MISSISSAUGA, ON, Oct. 8, 2024
/CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF)
("Cipher" or the "Company") announced today the
appointment of Hamed Ghanei as Chief
Business Officer ("CBO").
Craig Mull, Interim Chief
Executive Officer, commented on the appointment: "I am delighted to
announce the addition of Dr. Ghanei to Cipher's executive team.
Hamed's expertise in business development, including extensive
experience with licensing deals and other M&A opportunities in
the specialty pharmaceuticals and healthcare industries, make him
an excellent fit for contributing to Cipher's next phase of
substantial growth."
Dr. Ghanei has over 15 years of experience in specialty
pharmaceuticals, venture funds, and healthcare investment banking.
Throughout his career, he has led the evaluation of over 500
licensing and M&A opportunities and has been involved in five
commercial product launches. He has successfully negotiated over 20
transactions with total value exceeding $1
billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and
Biochemistry from the University of
Guelph, and a Ph.D. in Medical Biophysics from the
University of Toronto.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a
specialty pharmaceutical company with a robust and diversified
portfolio of commercial and early to late-stage products, mainly in
dermatology. Cipher acquires products that fulfill unmet medical
needs, manages the required clinical development and regulatory
approval process, and currently markets those products
in Canada, the U.S., and South America. For more
information, visit www.cipherpharma.com.
Forward-Looking Statements and Non-IFRS Measures
This document includes forward-looking statements within the
meaning of applicable securities laws. These forward-looking
statements include, among others, statements with respect to our
objectives and goals and strategies to achieve those objectives and
goals, as well as statements with respect to our beliefs, plans,
expectations, anticipations, estimates and intentions. The words
"may", "will", "could", "should", "would", "suspect", "outlook",
"believe", "plan", "anticipate", "estimate", "expect", "intend",
"forecast", "objective", "hope" and "continue" (or the negative
thereof), and words and expressions of similar import, are intended
to identify forward-looking statements. By nature, forward-looking
statements involve inherent risks and uncertainties, both general
and specific, which give rise to the possibility that predictions,
forecasts, projections and other forward-looking statements will
not be achieved. Certain material factors or assumptions are
applied in making forward-looking statements and actual results may
differ materially from those expressed or implied in such
statements. We caution readers not to place undue reliance on these
statements as a number of important factors, many of which are
beyond our control, could cause our actual results to differ
materially from the beliefs, plans, objectives, expectations,
anticipations, estimates and intentions expressed in such
forward-looking statements. These factors include, but are not
limited to, publication of negative results of clinical trials; our
ability to enter into development, manufacturing and marketing and
distribution agreements with other pharmaceutical companies and
keep such agreements in effect; our dependency on a limited number
of products; our dependency on protection from patents that will
expire; integration difficulties and other risks if we acquire or
in-license technologies or product candidates; reliance on third
parties for the marketing of certain products; product approval
process by regulators which can be highly unpredictable; the timing
of completion of clinical trials, regulatory submissions and
regulatory approvals; reliance on third parties to manufacture our
products and events outside of our control that could adversely
impact the ability of our manufacturing partners to supply products
to meet our demands; we may be subject to future product liability
claims; unexpected product safety or efficacy concerns may arise;
we generate license revenue from a limited number of distribution
and supply agreements; the pharmaceutical industry is highly
competitive with new competing product entrants; requirements for
additional capital to fund future operations; products may be
subject to pricing regulation; dependence on key managerial
personnel and external collaborators; certain of our products are
subject to regulation as controlled substances; limitations on
reimbursement in the healthcare industry; extent and impact of
health pandemic outbreaks on our business; unpredictable
development goals and projected time frames; rising insurance
costs; ability to enforce covenants not to compete; we may be
unsuccessful in evaluating material risks involved in completed and
future acquisitions; we may be unable to identify, acquire or
integrate acquisition targets successfully; compliance with privacy
and security regulation; our policies regarding product returns,
allowances and chargebacks may reduce revenues; additional
regulatory burden and controls over financial reporting; general
commercial litigation, class actions, other litigation claims and
regulatory actions; the difficulty for shareholders to realize
in the United States upon judgments of U.S. courts
predicated upon civil liability of the Company and its directors
and officers who are not residents of the United States; the potential violation of
intellectual property rights of third parties; our efforts to
obtain, protect or enforce our patents and other intellectual
property rights related to our products; changes in U.S., Canadian
or foreign patent laws; inability to protect our trademarks from
infringement; shareholders may be further diluted if we issue
securities to raise capital; volatility of our share price; the
fact that we have a significant shareholder; our operating results
may fluctuate significantly; and our debt obligations will have
priority over the common shares of the Company in the event of a
liquidation, dissolution or winding up. We caution that the
foregoing list of important factors that may affect future results
is not exhaustive. When reviewing our forward-looking statements,
investors and others should carefully consider the foregoing
factors and other uncertainties and potential events. Additional
information about factors that may cause actual results to differ
materially from expectations, and about material factors or
assumptions applied in making forward-looking statements, may be
found in the "Risk Factors" section of our MD&A for the year
ended December 31, 2023 and the
Company's Annual Information Form, and elsewhere in our filings
with Canadian securities regulators. Except as required by Canadian
securities law, we do not undertake to update any forward-looking
statements, whether written or oral, that may be made from time to
time by us or on our behalf; such statements speak only as of the
date made. The forward-looking statements included herein are
expressly qualified in their entirety by this cautionary
language.
SOURCE Cipher Pharmaceuticals Inc.